{"Title": ["PHAS To Begin COVID-19 Drug Trial In June, MRSN Hits New High, LJPC Plunges, RCUS On Watch", "Ironwood, AbbVie To Discontinue Development Of MD-7246 - Quick Facts", "IRWD Makes Bullish Cross Above Critical Moving Average", "Ironwood Pharmaceuticals Inc (IRWD) Q1 2020 Earnings Call Transcript", "First Week of November 20th Options Trading For Ironwood Pharmaceuticals (IRWD)", "Ironwood Pharmaceuticals Enters Oversold Territory (IRWD)", "Ironwood Pharmaceuticals Inc (IRWD) Q4 2019 Earnings Call Transcript", "Is Ironwood Pharmaceuticals Stock a Buy?", "PHAS To Begin COVID-19 Drug Trial In June, MRSN Hits New High, LJPC Plunges, RCUS On Watch", "Ironwood Pharmaceuticals Reaches Analyst Target Price", "Ironwood Pharmaceuticals Inc (IRWD) Q3 2019 Earnings Call Transcript", "Ironwood Pharmaceuticals Becomes Oversold (IRWD)", "Ironwood Pharmaceuticals' Blowout Q2 Results: What You'll Want to Know", "Ironwood Pharmaceuticals Inc (IRWD) Q2 2019 Earnings Call Transcript", "Health Care Sector Update for 06/19/2019: MLNT,IRWD,AGN,IQV,CALA", "Health Care Sector Update for 06/19/2019: IRWD,AGN,IQV,CALA", "Double Your Money with This Biotech", "Ironwood Pharmaceuticals Reaches Analyst Target Price", "Ironwood Pharmaceuticals Inc (IRWD) Q3 2019 Earnings Call Transcript", "Ironwood Pharmaceuticals Becomes Oversold (IRWD)", "Ironwood Pharmaceuticals' Blowout Q2 Results: What You'll Want to Know", "Ironwood Pharmaceuticals Inc (IRWD) Q2 2019 Earnings Call Transcript", "Health Care Sector Update for 06/19/2019: MLNT,IRWD,AGN,IQV,CALA", "Health Care Sector Update for 06/19/2019: IRWD,AGN,IQV,CALA", "Double Your Money with This Biotech", "Ironwood Pharmaceuticals Inc (IRWD) Q1 2019 Earnings Call Transcript", "Health Care Sector Update for 03/22/2019: LXRX,SNY,IRWD,IMMP,CNAT", "Health Care Sector Update for 03/22/2019: IRWD,IMMP,CNAT", "Why Is Ironwood (IRWD) Down 0.4% Since Last Earnings Report?", "Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise", "Ironwood to Get New CEO, Current CEO to Head Latest Spinoff", "Ironwood/Allergan Settle Linzess Patent Litigation With Mylan", "Ironwood Pharmaceuticals Inc (IRWD) Q4 2018 Earnings Conference Call Transcript", "Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q4 Earnings Expected to Decline", "Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid", "Ironwood Commences Phase I Study on IW-6463 for CNS Disorders", "Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C", "Health Care Sector Update for 01/15/2019: IRWD,KTOV,EW,BSX,ALNY", "Ironwood to Get New CEO, Current CEO to Head Latest Spinoff", "Ironwood/Allergan Settle Linzess Patent Litigation With Mylan", "Ironwood Pharmaceuticals Inc (IRWD) Q4 2018 Earnings Conference Call Transcript", "Relative Strength Alert For Ironwood Pharmaceuticals", "Why Is Ironwood (IRWD) Up 6.7% Since Last Earnings Report?", "Ironwood (IRWD) Q3 Earnings & Revenues Miss, Shares Down", "Ironwood Pharmaceuticals (IRWD) Reports Q3 Loss, Misses Revenue Estimates", "After Hours Most Active for Nov 1, 2018 : CZR, SBUX, MSFT, IRWD, CELG, AAPL", "Allergan (AGN) Beats on Q3 Earnings, Raises 2018 Guidance", "Novartis May Beat Ironwood Pharmaceuticals to the Punch", "Look Under The Hood: FTXH Has 35% Upside", "Relative Strength Alert For Ironwood Pharmaceuticals", "Why Is Ironwood (IRWD) Up 6.7% Since Last Earnings Report?", "Ironwood (IRWD) Q3 Earnings & Revenues Miss, Shares Down", "Ironwood Pharmaceuticals (IRWD) Reports Q3 Loss, Misses Revenue Estimates", "After Hours Most Active for Nov 1, 2018 : CZR, SBUX, MSFT, IRWD, CELG, AAPL", "Allergan (AGN) Beats on Q3 Earnings, Raises 2018 Guidance", "Novartis May Beat Ironwood Pharmaceuticals to the Punch", "Look Under The Hood: FTXH Has 35% Upside", "Relative Strength Alert For Ironwood Pharmaceuticals", "Why Is Ironwood (IRWD) Up 6.7% Since Last Earnings Report?", "Ironwood (IRWD) Q3 Earnings & Revenues Miss, Shares Down", "Ironwood Pharmaceuticals (IRWD) Reports Q3 Loss, Misses Revenue Estimates", "After Hours Most Active for Nov 1, 2018 : CZR, SBUX, MSFT, IRWD, CELG, AAPL", "Allergan (AGN) Beats on Q3 Earnings, Raises 2018 Guidance", "Novartis May Beat Ironwood Pharmaceuticals to the Punch", "Look Under The Hood: FTXH Has 35% Upside", "Ironwood Pharmaceuticals (IRWD) Q3 Earnings Preview: Here's What to Look Out For", "Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs", "Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down", "Pre-Market Earnings Report for August 6, 2018 : SRE, TSN, CAH, NWL, HSIC, VST, JEC, CFX, KOS, BID, IRWD, SEAS", "Ironwood Begins New Phase III Study to Expand Linzess Label", "Health Care Sector Update for 07/16/2018: OPK,GENE,DARE,IRWD,FMS", "Why Is Ironwood (IRWD) Up 0.9% Since Last Earnings Report?", "Ironwood Initiates Phase III Studies on Reflux Candidate", "Commit To Purchase Ironwood Pharmaceuticals At $15, Earn 16.2% Annualized Using Options", "Ironwood Pharmaceuticals (IRWD) Down 10.3% Since Earnings Report: Can It Rebound?", "Ironwood Pharmaceuticals Reaches Analyst Target Price", "Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring", "Bullish Two Hundred Day Moving Average Cross - IRWD", "Interesting IRWD Put And Call Options For November 16th", "Health Care Sector Update for 07/16/2018: GENE,IRWD", "Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up", "IRWD Crosses Above Average Analyst Target", "Interesting IRWD Put And Call Options For March 16th", "Here's Why Ironwood Pharmaceuticals, Inc. Stock Slipped 13.2% in December", "2018 Is a Critical Year for These 3 Small Commercial-Stage Biotech Stocks", "Ironwood Succeeds in Diabetic Hypertension Phase II Study", "Health Care Sector Update for 12/04/2017: MBIO,LOXO,IRWD", "First Week of April 20th Options Trading For Ironwood Pharmaceuticals (IRWD)", "Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up", "IRWD Crosses Above Average Analyst Target", "Interesting IRWD Put And Call Options For March 16th", "Here's Why Ironwood Pharmaceuticals, Inc. Stock Slipped 13.2% in December", "2018 Is a Critical Year for These 3 Small Commercial-Stage Biotech Stocks", "Ironwood Succeeds in Diabetic Hypertension Phase II Study", "Health Care Sector Update for 12/04/2017: MBIO,LOXO,IRWD", "First Week of April 20th Options Trading For Ironwood Pharmaceuticals (IRWD)", "Bullish Two Hundred Day Moving Average Cross - IRWD", "Here's What's Behind Synergy Pharmaceuticals' 15.6% Drop Today", "Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up", "Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up", "IRWD Makes Bullish Cross Above Critical Moving Average", "Why Synergy Pharmaceuticals Rallied 12% Today", "Why Is Ironwood (IRWD) Down 4.1% Since the Last Earnings Report?", "Health Care Sector Update for 12/04/2017: SUPN,LOXO,IRWD", "Interesting IRWD Put And Call Options For October 20th", "Ironwood Pharma's Combination Gout Drug Gets FDA Approval", "Here's Why Synergy Pharmaceuticals Inc. Is Falling Today", "Synergy Pharmaceuticals Inc. Tanked 14.2% in July -- but Why?", "Synergy Pharmaceuticals: Approval, Now What?", "Ironwood (IRWD) Q4 Loss Narrower than Expected; Sales Top", "Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS", "Ironwood (IRWD) Q1 Loss Wider than Expected, Sales Miss", "5 Drug Stocks Poised to Beat Earnings Estimates in Q4", "Why Synergy Pharmaceuticals Shares Fell 14.6% Today", "Ironwood/Astellas Report Positive Phase III Data on Linzess", "Ironwood-Allergan Linzess Gets FDA Approval in Lower Dose", "A David and Goliath Story: Can Small-Cap Synergy Pharmaceuticals Take on Ironwood Pharmaceuticals?", "Why Synergy Pharmaceuticals Is Jumping 10% Today", "Ironwood, Allergan Report Positive Linzess IBS-C Study Data", "Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?", "Ironwood (IRWD) Presents Positive Phase III Data on Zurampic", "Intercept (ICPT) Likely to Beat in Q2 Earnings: Stock to Gain?", "Exelixis (EXEL) Q2 Earnings Preview: Stock Likely to Gain?", "Aegerion (AEGR): What Awaits for the Stock in Q2 Earnings?", "What Awaits Aerie Pharmaceuticals (AERI) in Q2 Earnings?", "Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?", "Keryx (KERX) Q2 Earnings Preview: Will the Stock Gain?", "What's in Store for Merck KGaA (MKGAF) in Q2 Earnings?", "What Awaits Radius Health (RDUS) this Earnings Season?", "Intercept (ICPT) Likely to Beat in Q2 Earnings: Stock to Gain?", "Exelixis (EXEL) Q2 Earnings Preview: Stock Likely to Gain?", "Aegerion (AEGR): What Awaits for the Stock in Q2 Earnings?", "What Awaits Aerie Pharmaceuticals (AERI) in Q2 Earnings?", "Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?", "Keryx (KERX) Q2 Earnings Preview: Will the Stock Gain?", "What's in Store for Prothena (PRTA) This Earnings Season?", "Whta's in Store for Endocyte (ECYT) this Earnings Season?", "AmerisourceBergen (ABC) Q3 Earnings: Stock to Surprise?", "Mallinckrodt (MNK) Q3 Earnings: Will the Stock Surprise?", "McKesson (MCK) Q1 Earnings: Stock Likely to Beat?", "IRWD September 16th Options Begin Trading", "Noteworthy Tuesday Option Activity: VHC, AKAM, IRWD", "First Week of June 17th Options Trading For Ironwood Pharmaceuticals (IRWD)", "Health Care Sector Update for 07/15/2016: IRWD,AGN,ARDX,CYTR", "Ironwood/Allergan's Linzess sNDA Accepted for FDA Review", "Ironwood Slumps, Halts Development of Gastroparesis Drug", "IRWD Crosses Above Key Moving Average Level", "Why You Shouldn't Bet Against Ironwood Pharmaceuticals (IRWD) Stock", "Is This Ironwood Pharmaceuticals' Biggest Threat?", "Why Synergy Pharmaceuticals Shares Are Crashing 16% Today", "What's Behind Synergy Pharmaceuticals' Soaring Shares Today", "3 Biotech Stocks With Scary-High Debt-to-Capital Ratios", "3 Big Battles Brewing in Biotech", "Ironwood Slumps, Halts Development of Gastroparesis Drug", "IRWD Crosses Above Key Moving Average Level", "Why You Shouldn't Bet Against Ironwood Pharmaceuticals (IRWD) Stock", "Ironwood's Q3 Loss Wider than Expected, Revenues Miss", "3 Biotech Stocks to Buy in November", "Bullish Two Hundred Day Moving Average Cross - IRWD", "Commit To Buy Ironwood Pharmaceuticals At $7.50, Earn 24.1% Annualized Using Options", "Ironwood's Q4 Loss Narrower than Expected, Revenues Beat", "Oversold Conditions For Ironwood Pharmaceuticals", "Ironwood Highlights Strategic Objectives, Provides Outlook", "Ironwood/Astellas Report Positive Phase III Data on Linzess", "Ironwood's Q3 Loss Wider than Expected, Revenues Miss", "3 Biotech Stocks to Buy in November", "Bullish Two Hundred Day Moving Average Cross - IRWD", "Ironwood/Allergan to File for Lower Dose of Linzess in 1H16", "Ironwood Q1 Loss Wider-Than-Expected, Revenues Miss - Analyst Blog", "Actavis and Rhythm Start Mid-Stage Study on Relamorelin - Analyst Blog", "Why It's Not Too Late to Buy Exact Sciences Corporation", "Sucampo Pharmaceuticals Revamp Impresses Wall Street", "Theravance Biopharma's Velusetrag Enters Phase IIb Study - Analyst Blog", "Why Synergy Pharmaceuticals, Inc. Shares Are Surging Higher", "Health Care Sector Update for 06/10/2015: IRWD, CYTX, HLS", "Tuesday's ETF Movers: XOP, XBI", "Ironwood Pharmaceuticals Cuts Loss on Higher Revenues - Analyst Blog", "First Week of IRWD March 20th Options Trading", "Why Earnings Season Could Be Great for Ironwood Pharmaceuticals (IRWD) - Tale of the Tape", "Ironwood Pharmaceuticals Advances IW-9179 to Phase IIa - Analyst Blog", "Synergy Pharmaceuticals Drug Fares Well in Phase II Study - Analyst Blog", "Ironwood, Exact Sciences Ink Cologuard Co-Promotion Deal - Analyst Blog", "Ironwood Commences Dosing in Phase I Study on IW-1973 - Analyst Blog", "Ironwood Pharmaceuticals (IRWD) Falls: Stock Goes Down 5.3% - Tale of the Tape", "Sector Update: Health Care", "Sector Update: Health Stocks Lower Pre-Bell", "First Week of May 2015 Options Trading For Ironwood Pharmaceuticals", "IRWD Makes Notable Cross Below Critical Moving Average", "Synergy Pharma (SGYP) Posts Wider-than-Expected Loss in Q2 - Analyst Blog", "5 Things Actavis plc's Management Wants You to Know", "Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog", "Questcor (QCOR) Misses on Q2 Earnings, Beats on Revenues - Analyst Blog", "AcelRx Pharmaceuticals (ACRX) Jumps: Stock Adds 11.7% in Session - Tale of the Tape", "ImmunoGen (IMGN) Soars: Stock Up 8.8% - Tale of the Tape", "Synergy Pharmaceuticals Progresses with Mid-Stage Candidate - Analyst Blog", "Synergy Pharmaceuticals' Plecanatide to Move into Phase III - Analyst Blog", "Synergy Pharma Posts Narrower-than-Expected Q1 Loss - Analyst Blog", "Earnings Up at Jazz Pharmaceuticals, Revenue Guidance Raised - Analyst Blog", "Ironwood Pharmaceuticals Narrows Q2 Loss, Revenues Down - Analyst Blog", "Questcor (QCOR) Misses on Q2 Earnings, Beats on Revenues - Analyst Blog", "AcelRx Pharmaceuticals (ACRX) Jumps: Stock Adds 11.7% in Session - Tale of the Tape", "ImmunoGen (IMGN) Soars: Stock Up 8.8% - Tale of the Tape", "Synergy Pharmaceuticals Progresses with Mid-Stage Candidate - Analyst Blog", "Synergy Pharmaceuticals' Plecanatide to Move into Phase III - Analyst Blog", "Synergy Pharma Posts Narrower-than-Expected Q1 Loss - Analyst Blog", "Earnings Up at Jazz Pharmaceuticals, Revenue Guidance Raised - Analyst Blog", "Healthcare Stocks Trailing Broader Markets; Ironwood Pharma Climbing in Late Trade After Beating Q1 Estimates", "Sector Update: Healthcare", "Tuesday's ETF Movers: XBI, REM", "Valeant Eyes Allergan - Analyst Blog", "Interesting IRWD Put And Call Options For June 21st", "Why Ironwood Pharmaceuticals (IRWD) is Poised to Beat Earnings Estimates (Again) - Tale of the Tape", "IRWD Makes Bullish Cross Above Critical Moving Average", "Ironwood Up as Loss Narrows, Linzess Shines - Analyst Blog", "First Week of April 19th Options Trading For Ironwood Pharmaceuticals (IRWD)", "Pre-Market Most Active for Feb 12, 2014 : NOK, ATO, PBR/A, FSL, MT, ABB, OPTT, CSIQ, QQQ, IRWD, FB, TRIP", "Narrower-than-Expected Loss at Ironwood, Shares Up - Analyst Blog", "Key Pharmaceutical Stocks Ready to Deliver Earnings Beats - Earnings ESP", "Ironwood Pharmaceuticals, Inc. (IRWD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report", "Ironwood Up on Job Cut Plans - Analyst Blog", "Should You Worry About the Short Interest in Ironwood Pharmaceuticals, Inc. (IRWD)? - Tale of the Tape", "Ironwood Initiates GERD Study, Shares Up - Analyst Blog", "First Week of April 19th Options Trading For Ironwood Pharmaceuticals (IRWD)", "Pre-Market Most Active for Feb 12, 2014 : NOK, ATO, PBR/A, FSL, MT, ABB, OPTT, CSIQ, QQQ, IRWD, FB, TRIP", "Narrower-than-Expected Loss at Ironwood, Shares Up - Analyst Blog", "Key Pharmaceutical Stocks Ready to Deliver Earnings Beats - Earnings ESP", "Ironwood Pharmaceuticals, Inc. (IRWD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report", "Ironwood Up on Job Cut Plans - Analyst Blog", "Should You Worry About the Short Interest in Ironwood Pharmaceuticals, Inc. (IRWD)? - Tale of the Tape", "Ironwood Initiates GERD Study, Shares Up - Analyst Blog", "Update on Ironwood Pharma - Analyst Blog", "Largest option trades in equities", "Synergy Pharma's Q3 Loss Narrower than Expected - Analyst Blog", "Pipeline Progress at Synergy Pharma - Analyst Blog", "Weekly 3-Year Low Highlight: EXC, RVBD, IRWD, SHOS", "Roche and Inovio Tie Up - Analyst Blog", "Data on Auxilium Pharma's Xiaflex - Analyst Blog", "Discovery Labs Surges on Surfaxin News - Analyst Blog", "Forest's Patent Infringement Lawsuits - Analyst Blog", "Synergy Pharma's Pipeline Holds Promise - Analyst Blog", "Ironwood and AstraZeneca Initiate Study - Analyst Blog", "Positive News on Roche's Perjeta - Analyst Blog", "Data on Novartis' Ultibro Breezhaler - Analyst Blog", "Roche and Inovio Tie Up - Analyst Blog", "Data on Auxilium Pharma's Xiaflex - Analyst Blog", "Novartis' Ilaris Approved for SJIA in Europe - Analyst Blog", "Setback for ArQule - Analyst Blog", "Data on Novartis' RLX030 - Analyst Blog", "Encouraging Data on Roche's Lampalizumab - Analyst Blog", "FDA Designation for CPRX's Firdapse - Analyst Blog", "Astellas' Astagraf XL Launched in U.S. - Analyst Blog", "Investors are Betting Against Ironwood Pharmaceuticals, Inc. (IRWD), Should You? - Tale of the Tape", "Otsuka Pharma to Acquire Astex Pharma, Shares Up - Analyst Blog", "Loss Narrows at Synergy Pharma in Q2 - Analyst Blog", "Corcept's Q2 Loss In-Line with Expectations - Analyst Blog", "Valeant Tops on Earnings, Ups Guidance - Analyst Blog", "Valeant Acquires Bausch + Lomb - Analyst Blog", "Pipeline Progress at Synergy Pharma - Analyst Blog", "Loss Widens at Ironwood - Analyst Blog", "Will Forest Labs (FRX) Beat Earnings Estimates This Quarter? - Analyst Blog", "Breakthrough Therapy for Novartis - Analyst Blog", "Positive Data from Synergy Pharma - Analyst Blog", "Ironwood Pharma Prices Stock Offering - Analyst Blog", "Pre-Market Most Active for May 22, 2013 : NTAP, PFE, NMR, RDS/A, RDS/B, NOK, SNE, PGTI, IRWD, GILD, VOD, ZNGA", "Loss Widens at Ironwood - Analyst Blog", "Loss Widens at IRWD on Higher Costs - Analyst Blog", "Alkermes Maintains Fiscal 2013 View - Analyst Blog", "Forest Settles with Glenmark - Analyst Blog", "IRWD Launches Constella in Europe - Analyst Blog", "Positive Data from Synergy Pharma - Analyst Blog", "Ironwood Pharma Prices Stock Offering - Analyst Blog", "Pre-Market Most Active for May 22, 2013 : NTAP, PFE, NMR, RDS/A, RDS/B, NOK, SNE, PGTI, IRWD, GILD, VOD, ZNGA", "Loss Widens at Ironwood - Analyst Blog", "Loss Widens at IRWD on Higher Costs - Analyst Blog", "Alkermes Maintains Fiscal 2013 View - Analyst Blog", "Forest Settles with Glenmark - Analyst Blog", "IRWD Launches Constella in Europe - Analyst Blog", "Positive Results on SGYP Candidate - Analyst Blog", "Ironwood Pharma Upped to Strong Buy - Analyst Blog", "Forest Labs-Glenmark Tie Up - Analyst Blog", "Pipeline Progress at Synergy Pharma - Analyst Blog", "Ironwood Anxiety Drug in Phase I - Analyst Blog", "Cubist Pharma Seeks Label Expansion - Analyst Blog", "Forest Launches Two Products - Analyst Blog", "Patent Challenge for Auxilium Pharma - Analyst Blog", "Positive Results on SGYP Candidate - Analyst Blog", "Forest Hit by Lexapro Generics - Analyst Blog", "Delay in Forest Drug FDA Action Date - Analyst Blog", "Ironwood Pharma Beats on All Fronts - Analyst Blog", "CHMP Positive on Ironwood's Constella - Analyst Blog", "FDA OK's Forest-Ironwood's Linzess - Analyst Blog", "Hedging Ironwood before ruling", "Forest Files Cariprazine NDA - Analyst Blog"], "Elapsed Time": ["MAY 28, 2020", "MAY 27, 2020", "MAY 11, 2020", "MAY 7, 2020", "MAR 27, 2020", "MAR 18, 2020", "FEB 13, 2020", "FEB 12, 2020", "MAY 28, 2020", "DEC 18, 2019", "OCT 31, 2019", "OCT 3, 2019", "JUL 31, 2019", "JUL 31, 2019", "JUN 19, 2019", "JUN 19, 2019", "JAN 24, 2020", "DEC 18, 2019", "OCT 31, 2019", "OCT 3, 2019", "JUL 31, 2019", "JUL 31, 2019", "JUN 19, 2019", "JUN 19, 2019", "JAN 24, 2020", "MAY 2, 2019", "MAR 22, 2019", "MAR 22, 2019", "MAR 15, 2019", "FEB 14, 2019", "JAN 7, 2019", "JAN 3, 2019", "FEB 13, 2019", "FEB 6, 2019", "JAN 29, 2019", "JAN 24, 2019", "JAN 16, 2019", "JAN 15, 2019", "JAN 7, 2019", "JAN 3, 2019", "DEC 17, 2018", "DEC 13, 2018", "DEC 6, 2018", "NOV 8, 2018", "NOV 6, 2018", "NOV 1, 2018", "OCT 30, 2018", "OCT 30, 2018", "DEC 17, 2018", "DEC 13, 2018", "DEC 6, 2018", "NOV 8, 2018", "NOV 6, 2018", "NOV 1, 2018", "OCT 30, 2018", "OCT 30, 2018", "DEC 17, 2018", "DEC 13, 2018", "DEC 6, 2018", "NOV 8, 2018", "NOV 6, 2018", "NOV 1, 2018", "OCT 30, 2018", "OCT 30, 2018", "DEC 17, 2018", "OCT 25, 2018", "AUG 14, 2018", "AUG 7, 2018", "AUG 3, 2018", "JUL 17, 2018", "JUL 16, 2018", "SEP 5, 2018", "JUN 22, 2018", "JUN 19, 2018", "MAY 31, 2018", "MAY 31, 2018", "MAY 2, 2018", "APR 9, 2018", "MAR 13, 2018", "JUL 16, 2018", "FEB 16, 2018", "JAN 29, 2018", "JAN 25, 2018", "JAN 4, 2018", "DEC 10, 2017", "DEC 5, 2017", "DEC 4, 2017", "FEB 23, 2018", "FEB 16, 2018", "JAN 29, 2018", "JAN 25, 2018", "JAN 4, 2018", "DEC 10, 2017", "DEC 5, 2017", "DEC 4, 2017", "FEB 23, 2018", "NOV 28, 2017", "NOV 14, 2017", "NOV 3, 2017", "OCT 12, 2017", "OCT 5, 2017", "SEP 29, 2017", "SEP 4, 2017", "DEC 4, 2017", "AUG 23, 2017", "AUG 22, 2017", "AUG 10, 2017", "AUG 8, 2017", "MAR 13, 2017", "FEB 22, 2017", "FEB 20, 2017", "MAY 9, 2017", "FEB 9, 2017", "FEB 1, 2017", "JAN 30, 2017", "JAN 27, 2017", "JAN 5, 2017", "DEC 23, 2016", "DEC 23, 2016", "FEB 17, 2017", "AUG 2, 2016", "AUG 2, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "JUL 29, 2016", "AUG 2, 2016", "AUG 2, 2016", "AUG 2, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "JUL 29, 2016", "JUL 29, 2016", "JUL 28, 2016", "JUL 27, 2016", "JUL 27, 2016", "JUL 25, 2016", "JUL 18, 2016", "APR 26, 2016", "APR 19, 2016", "JUL 15, 2016", "JUN 10, 2016", "APR 6, 2016", "MAR 31, 2016", "MAR 29, 2016", "MAR 21, 2016", "MAR 18, 2016", "APR 19, 2016", "APR 11, 2016", "APR 10, 2016", "APR 6, 2016", "MAR 31, 2016", "DEC 1, 2015", "NOV 4, 2015", "NOV 1, 2015", "MAR 7, 2016", "FEB 19, 2016", "FEB 19, 2016", "JAN 19, 2016", "JAN 12, 2016", "DEC 1, 2015", "NOV 4, 2015", "NOV 1, 2015", "MAR 7, 2016", "OCT 14, 2015", "MAY 6, 2015", "APR 9, 2015", "MAR 19, 2015", "MAR 17, 2015", "MAR 13, 2015", "JUN 17, 2015", "JUN 10, 2015", "FEB 17, 2015", "FEB 13, 2015", "JAN 26, 2015", "JAN 16, 2015", "DEC 10, 2014", "NOV 20, 2014", "MAR 10, 2015", "MAR 6, 2015", "OCT 17, 2014", "OCT 16, 2014", "OCT 16, 2014", "SEP 25, 2014", "AUG 21, 2014", "AUG 13, 2014", "NOV 12, 2014", "AUG 5, 2014", "JUL 25, 2014", "JUL 21, 2014", "JUL 21, 2014", "JUL 18, 2014", "JUL 9, 2014", "MAY 14, 2014", "AUG 6, 2014", "AUG 5, 2014", "JUL 25, 2014", "JUL 21, 2014", "JUL 21, 2014", "JUL 18, 2014", "JUL 9, 2014", "MAY 14, 2014", "AUG 6, 2014", "APR 29, 2014", "APR 29, 2014", "APR 29, 2014", "APR 24, 2014", "APR 23, 2014", "APR 23, 2014", "APR 22, 2014", "APR 30, 2014", "FEB 26, 2014", "FEB 12, 2014", "JAN 22, 2014", "JAN 16, 2014", "JAN 15, 2014", "JAN 10, 2014", "DEC 27, 2013", "MAR 19, 2014", "FEB 26, 2014", "FEB 12, 2014", "JAN 22, 2014", "JAN 16, 2014", "JAN 15, 2014", "JAN 10, 2014", "DEC 27, 2013", "MAR 19, 2014", "DEC 16, 2013", "DEC 11, 2013", "NOV 15, 2013", "NOV 4, 2013", "OCT 27, 2013", "SEP 11, 2013", "OCT 11, 2013", "OCT 7, 2013", "OCT 7, 2013", "OCT 4, 2013", "SEP 16, 2013", "SEP 13, 2013", "SEP 12, 2013", "SEP 11, 2013", "OCT 11, 2013", "SEP 5, 2013", "SEP 4, 2013", "SEP 3, 2013", "AUG 30, 2013", "AUG 28, 2013", "AUG 23, 2013", "AUG 22, 2013", "SEP 6, 2013", "AUG 16, 2013", "AUG 12, 2013", "AUG 8, 2013", "AUG 7, 2013", "AUG 6, 2013", "JUL 24, 2013", "JUL 22, 2013", "AUG 21, 2013", "MAY 24, 2013", "MAY 23, 2013", "MAY 22, 2013", "APR 24, 2013", "JAN 16, 2013", "JAN 9, 2013", "JAN 9, 2013", "JUN 17, 2013", "MAY 24, 2013", "MAY 23, 2013", "MAY 22, 2013", "APR 24, 2013", "JAN 16, 2013", "JAN 9, 2013", "JAN 9, 2013", "JUN 17, 2013", "JAN 3, 2013", "JAN 3, 2013", "DEC 31, 2012", "DEC 31, 2012", "DEC 27, 2012", "DEC 24, 2012", "DEC 19, 2012", "JAN 4, 2013", "JAN 3, 2013", "APR 17, 2012", "OCT 26, 2012", "OCT 18, 2012", "SEP 27, 2012", "AUG 31, 2012", "AUG 28, 2012", "DEC 4, 2012"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/phas-to-begin-covid-19-drug-trial-in-june-mrsn-hits-new-high-ljpc-plunges-rcus-on-watch", "https://www.nasdaq.com/articles/ironwood-abbvie-to-discontinue-development-of-md-7246-quick-facts-2020-05-27", "https://www.nasdaq.com/articles/irwd-makes-bullish-cross-above-critical-moving-average-2020-05-11", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-inc-irwd-q1-2020-earnings-call-transcript-2020-05-08", "https://www.nasdaq.com/articles/first-week-of-november-20th-options-trading-for-ironwood-pharmaceuticals-irwd-2020-03-27", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-enters-oversold-territory-irwd-2020-03-18", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-inc-irwd-q4-2019-earnings-call-transcript-2020-02-14", "https://www.nasdaq.com/articles/is-ironwood-pharmaceuticals-stock-a-buy-2020-02-12", "https://www.nasdaq.com/articles/phas-to-begin-covid-19-drug-trial-in-june-mrsn-hits-new-high-ljpc-plunges-rcus-on-watch", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-reaches-analyst-target-price-2019-12-18", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-inc-irwd-q3-2019-earnings-call-transcript-2019-10-31", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-becomes-oversold-irwd-2019-10-03", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-blowout-q2-results%3A-what-youll-want-to-know-2019-07-31", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-inc-irwd-q2-2019-earnings-call-transcript-2019-07-31", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-19-2019%3A-mlntirwdagniqvcala-2019-06-19", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-19-2019%3A-irwdagniqvcala-2019-06-19", "https://www.nasdaq.com/articles/double-your-money-with-this-biotech-2020-01-24", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-reaches-analyst-target-price-2019-12-18", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-inc-irwd-q3-2019-earnings-call-transcript-2019-10-31", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-becomes-oversold-irwd-2019-10-03", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-blowout-q2-results%3A-what-youll-want-to-know-2019-07-31", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-inc-irwd-q2-2019-earnings-call-transcript-2019-07-31", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-19-2019%3A-mlntirwdagniqvcala-2019-06-19", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-19-2019%3A-irwdagniqvcala-2019-06-19", "https://www.nasdaq.com/articles/double-your-money-with-this-biotech-2020-01-24", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-inc-irwd-q1-2019-earnings-call-transcript-2019-05-03", "https://www.nasdaq.com/articles/health-care-sector-update-03222019-lxrxsnyirwdimmpcnat-2019-03-22", "https://www.nasdaq.com/articles/health-care-sector-update-03222019-irwdimmpcnat-2019-03-22", "https://www.nasdaq.com/articles/why-is-ironwood-irwd-down-0.4-since-last-earnings-report-2019-03-15", "https://www.nasdaq.com/articles/ironwood-irwd-q4-earnings-revenues-beat-shares-rise-2019-02-14", "https://www.nasdaq.com/articles/ironwood-to-get-new-ceo-current-ceo-to-head-latest-spinoff-2019-01-07", "https://www.nasdaq.com/articles/ironwood-allergan-settle-linzess-patent-litigation-with-mylan-2019-01-03", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-inc-irwd-q4-2018-earnings-conference-call-transcript-2019-02-13", "https://www.nasdaq.com/articles/earnings-preview%3A-ironwood-pharmaceuticals-irwd-q4-earnings-expected-to-decline-2019-02-06", "https://www.nasdaq.com/articles/allergan-agn-q4-earnings-beat-estimates-2019-view-tepid-2019-01-29", "https://www.nasdaq.com/articles/ironwood-commences-phase-i-study-on-iw-6463-for-cns-disorders-2019-01-24", "https://www.nasdaq.com/articles/ironwoods-irwd-linzess-gets-approval-in-china-for-ibs-c-2019-01-16", "https://www.nasdaq.com/articles/health-care-sector-update-01152019-irwdktovewbsxalny-2019-01-15", "https://www.nasdaq.com/articles/ironwood-to-get-new-ceo-current-ceo-to-head-latest-spinoff-2019-01-07", "https://www.nasdaq.com/articles/ironwood-allergan-settle-linzess-patent-litigation-with-mylan-2019-01-03", "https://www.nasdaq.com/articles/look-under-hood-ftxh-has-35-upside-2018-12-17", "https://www.nasdaq.com/articles/relative-strength-alert-ironwood-pharmaceuticals-2018-12-13", "https://www.nasdaq.com/articles/why-is-ironwood-irwd-up-6.7-since-last-earnings-report-2018-12-06", "https://www.nasdaq.com/articles/ironwood-irwd-q3-earnings-revenues-miss-shares-down-2018-11-08", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-irwd-reports-q3-loss-misses-revenue-estimates-2018-11-06", "https://www.nasdaq.com/articles/after-hours-most-active-nov-1-2018-czr-sbux-msft-irwd-celg-aapl-2018-11-01", "https://www.nasdaq.com/articles/allergan-agn-beats-on-q3-earnings-raises-2018-guidance-2018-10-30", "https://www.nasdaq.com/articles/novartis-may-beat-ironwood-pharmaceuticals-punch-2018-10-30", "https://www.nasdaq.com/articles/look-under-hood-ftxh-has-35-upside-2018-12-17", "https://www.nasdaq.com/articles/relative-strength-alert-ironwood-pharmaceuticals-2018-12-13", "https://www.nasdaq.com/articles/why-is-ironwood-irwd-up-6.7-since-last-earnings-report-2018-12-06", "https://www.nasdaq.com/articles/ironwood-irwd-q3-earnings-revenues-miss-shares-down-2018-11-08", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-irwd-reports-q3-loss-misses-revenue-estimates-2018-11-06", "https://www.nasdaq.com/articles/after-hours-most-active-nov-1-2018-czr-sbux-msft-irwd-celg-aapl-2018-11-01", "https://www.nasdaq.com/articles/allergan-agn-beats-on-q3-earnings-raises-2018-guidance-2018-10-30", "https://www.nasdaq.com/articles/novartis-may-beat-ironwood-pharmaceuticals-punch-2018-10-30", "https://www.nasdaq.com/articles/look-under-hood-ftxh-has-35-upside-2018-12-17", "https://www.nasdaq.com/articles/relative-strength-alert-ironwood-pharmaceuticals-2018-12-13", "https://www.nasdaq.com/articles/why-is-ironwood-irwd-up-6.7-since-last-earnings-report-2018-12-06", "https://www.nasdaq.com/articles/ironwood-irwd-q3-earnings-revenues-miss-shares-down-2018-11-08", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-irwd-reports-q3-loss-misses-revenue-estimates-2018-11-06", "https://www.nasdaq.com/articles/after-hours-most-active-nov-1-2018-czr-sbux-msft-irwd-celg-aapl-2018-11-01", "https://www.nasdaq.com/articles/allergan-agn-beats-on-q3-earnings-raises-2018-guidance-2018-10-30", "https://www.nasdaq.com/articles/novartis-may-beat-ironwood-pharmaceuticals-punch-2018-10-30", "https://www.nasdaq.com/articles/look-under-hood-ftxh-has-35-upside-2018-12-17", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-irwd-q3-earnings-preview%3A-heres-what-to-look-out-for-2018-10-25", "https://www.nasdaq.com/articles/ironwood-rides-on-linzess-progress-stalls-lenisurad-drugs-2018-08-14", "https://www.nasdaq.com/articles/ironwood-irwd-q2-earnings-revenues-miss-shares-down-2018-08-07", "https://www.nasdaq.com/articles/pre-market-earnings-report-august-6-2018-sre-tsn-cah-nwl-hsic-vst-jec-cfx-kos-bid-irwd", "https://www.nasdaq.com/articles/ironwood-begins-new-phase-iii-study-to-expand-linzess-label-2018-07-17", "https://www.nasdaq.com/articles/health-care-sector-update-07162018-opkgenedareirwdfms-2018-07-16", "https://www.nasdaq.com/articles/why-is-ironwood-irwd-up-0.9-since-last-earnings-report-2018-09-05", "https://www.nasdaq.com/articles/ironwood-initiates-phase-iii-studies-on-reflux-candidate-2018-06-22", "https://www.nasdaq.com/articles/commit-purchase-ironwood-pharmaceuticals-15-earn-162-annualized-using-options-2018-06-19", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-irwd-down-10.3-since-earnings-report%3A-can-it-rebound-2018-05-31", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-reaches-analyst-target-price-2018-05-31", "https://www.nasdaq.com/articles/ironwood-irwd-incurs-loss-in-q1-announces-restructuring-2018-05-02", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-irwd-2018-04-09", "https://www.nasdaq.com/articles/interesting-irwd-put-and-call-options-november-16th-2018-03-13", "https://www.nasdaq.com/articles/health-care-sector-update-07162018-geneirwd-2018-07-16", "https://www.nasdaq.com/articles/ironwood-irwd-beats-estimates-in-q4-earnings-stock-up-2018-02-16", "https://www.nasdaq.com/articles/irwd-crosses-above-average-analyst-target-2018-01-29", "https://www.nasdaq.com/articles/interesting-irwd-put-and-call-options-march-16th-2018-01-25", "https://www.nasdaq.com/articles/heres-why-ironwood-pharmaceuticals-inc-stock-slipped-132-december-2018-01-04", "https://www.nasdaq.com/articles/2018-critical-year-these-3-small-commercial-stage-biotech-stocks-2017-12-10", "https://www.nasdaq.com/articles/ironwood-succeeds-in-diabetic-hypertension-phase-ii-study-2017-12-05", "https://www.nasdaq.com/articles/health-care-sector-update-12042017-mbioloxoirwd-2017-12-04", "https://www.nasdaq.com/articles/first-week-april-20th-options-trading-ironwood-pharmaceuticals-irwd-2018-02-23", "https://www.nasdaq.com/articles/ironwood-irwd-beats-estimates-in-q4-earnings-stock-up-2018-02-16", "https://www.nasdaq.com/articles/irwd-crosses-above-average-analyst-target-2018-01-29", "https://www.nasdaq.com/articles/interesting-irwd-put-and-call-options-march-16th-2018-01-25", "https://www.nasdaq.com/articles/heres-why-ironwood-pharmaceuticals-inc-stock-slipped-132-december-2018-01-04", "https://www.nasdaq.com/articles/2018-critical-year-these-3-small-commercial-stage-biotech-stocks-2017-12-10", "https://www.nasdaq.com/articles/ironwood-succeeds-in-diabetic-hypertension-phase-ii-study-2017-12-05", "https://www.nasdaq.com/articles/health-care-sector-update-12042017-mbioloxoirwd-2017-12-04", "https://www.nasdaq.com/articles/first-week-april-20th-options-trading-ironwood-pharmaceuticals-irwd-2018-02-23", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-irwd-2017-11-28", "https://www.nasdaq.com/articles/heres-whats-behind-synergy-pharmaceuticals-156-drop-today-2017-11-14", "https://www.nasdaq.com/articles/ironwood-irwd-beats-estimates-in-q3-earnings-stock-up-2017-11-03", "https://www.nasdaq.com/articles/ardelyx-ibs-c-candidate-succeeds-in-pivotal-study-stock-up-2017-10-12", "https://www.nasdaq.com/articles/irwd-makes-bullish-cross-above-critical-moving-average-2017-10-05", "https://www.nasdaq.com/articles/why-synergy-pharmaceuticals-rallied-12-today-2017-09-29", "https://www.nasdaq.com/articles/why-is-ironwood-irwd-down-4.1-since-the-last-earnings-report-2017-09-04", "https://www.nasdaq.com/articles/health-care-sector-update-12042017-supnloxoirwd-2017-12-04", "https://www.nasdaq.com/articles/interesting-irwd-put-and-call-options-october-20th-2017-08-23", "https://www.nasdaq.com/articles/ironwood-pharmas-combination-gout-drug-gets-fda-approval-2017-08-22", "https://www.nasdaq.com/articles/heres-why-synergy-pharmaceuticals-inc-falling-today-2017-08-10", "https://www.nasdaq.com/articles/irwd-crosses-above-average-analyst-target-2017-03-15", "https://www.nasdaq.com/articles/synergy-pharmaceuticals-approval-now-what-2017-03-13", "https://www.nasdaq.com/articles/ironwood-irwd-q4-loss-narrower-than-expected-sales-top-2017-02-22", "https://www.nasdaq.com/articles/drug-stocks-q4-earnings-lineup-for-feb-21%3A-irwd-mnta-exas-2017-02-20", "https://www.nasdaq.com/articles/ironwood-irwd-q1-loss-wider-than-expected-sales-miss-2017-05-09", "https://www.nasdaq.com/articles/5-drug-stocks-poised-beat-earnings-estimates-q4-2017-02-09", "https://www.nasdaq.com/articles/why-synergy-pharmaceuticals-shares-fell-146-today-2017-02-01", "https://www.nasdaq.com/articles/ironwood-astellas-report-positive-phase-iii-data-on-linzess-2017-01-30", "https://www.nasdaq.com/articles/ironwood-allergan-linzess-gets-fda-approval-in-lower-dose-2017-01-27", "https://www.nasdaq.com/articles/david-and-goliath-story-can-small-cap-synergy-pharmaceuticals-take-ironwood", "https://www.nasdaq.com/articles/why-synergy-pharmaceuticals-jumping-10-today-2016-12-23", "https://www.nasdaq.com/articles/ironwood-allergan-report-positive-linzess-ibs-c-study-data-2016-12-23", "https://www.nasdaq.com/articles/radius-health-rdus-q4-earnings%3A-will-the-stock-disappoint-2017-02-17", "https://www.nasdaq.com/articles/what-awaits-radius-health-rdus-this-earnings-season-2016-08-02", "https://www.nasdaq.com/articles/intercept-icpt-likely-to-beat-in-q2-earnings%3A-stock-to-gain-2016-08-02", "https://www.nasdaq.com/articles/exelixis-exel-q2-earnings-preview%3A-stock-likely-to-gain-2016-08-01", "https://www.nasdaq.com/articles/aegerion-aegr%3A-what-awaits-for-the-stock-in-q2-earnings-2016-08-01", "https://www.nasdaq.com/articles/what-awaits-aerie-pharmaceuticals-aeri-in-q2-earnings-2016-08-01", "https://www.nasdaq.com/articles/merrimack-mack%3A-can-the-stock-surprise-in-q2-earnings-2016-08-01", "https://www.nasdaq.com/articles/keryx-kerx-q2-earnings-preview%3A-will-the-stock-gain-2016-07-29", "https://www.nasdaq.com/articles/whats-in-store-for-merck-kgaa-mkgaf-in-q2-earnings-2016-08-02", "https://www.nasdaq.com/articles/what-awaits-radius-health-rdus-this-earnings-season-2016-08-02", "https://www.nasdaq.com/articles/intercept-icpt-likely-to-beat-in-q2-earnings%3A-stock-to-gain-2016-08-02", "https://www.nasdaq.com/articles/exelixis-exel-q2-earnings-preview%3A-stock-likely-to-gain-2016-08-01", "https://www.nasdaq.com/articles/aegerion-aegr%3A-what-awaits-for-the-stock-in-q2-earnings-2016-08-01", "https://www.nasdaq.com/articles/what-awaits-aerie-pharmaceuticals-aeri-in-q2-earnings-2016-08-01", "https://www.nasdaq.com/articles/merrimack-mack%3A-can-the-stock-surprise-in-q2-earnings-2016-08-01", "https://www.nasdaq.com/articles/keryx-kerx-q2-earnings-preview%3A-will-the-stock-gain-2016-07-29", "https://www.nasdaq.com/articles/whats-in-store-for-prothena-prta-this-earnings-season-2016-07-29", "https://www.nasdaq.com/articles/whtas-in-store-for-endocyte-ecyt-this-earnings-season-2016-07-28", "https://www.nasdaq.com/articles/amerisourcebergen-abc-q3-earnings%3A-stock-to-surprise-2016-07-27", "https://www.nasdaq.com/articles/mallinckrodt-mnk-q3-earnings%3A-will-the-stock-surprise-2016-07-27", "https://www.nasdaq.com/articles/mckesson-mck-q1-earnings%3A-stock-likely-to-beat-2016-07-25", "https://www.nasdaq.com/articles/irwd-september-16th-options-begin-trading-2016-07-18", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-vhc-akam-irwd-2016-04-26", "https://www.nasdaq.com/articles/first-week-june-17th-options-trading-ironwood-pharmaceuticals-irwd-2016-04-19", "https://www.nasdaq.com/articles/health-care-sector-update-07152016-irwdagnardxcytr-2016-07-15", "https://www.nasdaq.com/articles/ironwood-allergans-linzess-snda-accepted-for-fda-review-2016-06-10", "https://www.nasdaq.com/articles/ironwood-slumps-halts-development-of-gastroparesis-drug-2016-04-06", "https://www.nasdaq.com/articles/irwd-crosses-above-key-moving-average-level-2016-03-31", "https://www.nasdaq.com/articles/why-you-shouldnt-bet-against-ironwood-pharmaceuticals-irwd-stock-2016-03-29", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-biggest-threat-2016-03-21", "https://www.nasdaq.com/articles/why-synergy-pharmaceuticals-shares-are-crashing-16-today-2016-03-18", "https://www.nasdaq.com/articles/whats-behind-synergy-pharmaceuticals-soaring-shares-today-2016-04-19", "https://www.nasdaq.com/articles/3-biotech-stocks-scary-high-debt-capital-ratios-2016-04-11", "https://www.nasdaq.com/articles/3-big-battles-brewing-biotech-2016-04-10", "https://www.nasdaq.com/articles/ironwood-slumps-halts-development-of-gastroparesis-drug-2016-04-06", "https://www.nasdaq.com/articles/irwd-crosses-above-key-moving-average-level-2016-03-31", "https://www.nasdaq.com/articles/ironwood-astellas-report-positive-phase-iii-data-on-linzess-2015-12-01", "https://www.nasdaq.com/articles/ironwoods-q3-loss-wider-than-expected-revenues-miss-2015-11-04", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-november-2015-11-01", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-irwd-2016-03-07", "https://www.nasdaq.com/articles/commit-buy-ironwood-pharmaceuticals-750-earn-241-annualized-using-options-2016-02-19", "https://www.nasdaq.com/articles/ironwoods-q4-loss-narrower-than-expected-revenues-beat-2016-02-19", "https://www.nasdaq.com/articles/oversold-conditions-ironwood-pharmaceuticals-2016-01-19", "https://www.nasdaq.com/articles/ironwood-highlights-strategic-objectives-provides-outlook-2016-01-12", "https://www.nasdaq.com/articles/ironwood-astellas-report-positive-phase-iii-data-on-linzess-2015-12-01", "https://www.nasdaq.com/articles/ironwoods-q3-loss-wider-than-expected-revenues-miss-2015-11-04", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-november-2015-11-01", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-irwd-2016-03-07", "https://www.nasdaq.com/articles/ironwood-allergan-to-file-for-lower-dose-of-linzess-in-1h16-2015-10-14", "https://www.nasdaq.com/articles/ironwood-q1-loss-wider-expected-revenues-miss-analyst-blog-2015-05-06", "https://www.nasdaq.com/articles/actavis-and-rhythm-start-mid-stage-study-on-relamorelin-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/why-its-not-too-late-buy-exact-sciences-corporation-2015-03-19", "https://www.nasdaq.com/articles/sucampo-pharmaceuticals-revamp-impresses-wall-street-2015-03-17", "https://www.nasdaq.com/articles/theravance-biopharmas-velusetrag-enters-phase-iib-study-analyst-blog-2015-03-13", "https://www.nasdaq.com/articles/why-synergy-pharmaceuticals-inc-shares-are-surging-higher-2015-06-17", "https://www.nasdaq.com/articles/health-care-sector-update-06102015-irwd-cytx-hls-2015-06-10", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-irwd-falls%3A-stock-goes-down-5.3-tale-of-the-tape-2015-02-17", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-cuts-loss-on-higher-revenues-analyst-blog-2015-02-13", "https://www.nasdaq.com/articles/first-week-irwd-march-20th-options-trading-2015-01-26", "https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-ironwood-pharmaceuticals-irwd-tale-of-the-tape-2015", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-advances-iw-9179-to-phase-iia-analyst-blog-2014-12-10", "https://www.nasdaq.com/articles/synergy-pharmaceuticals-drug-fares-well-in-phase-ii-study-analyst-blog-2014-11-20", "https://www.nasdaq.com/articles/ironwood-exact-sciences-ink-cologuard-co-promotion-deal-analyst-blog-2015-03-10", "https://www.nasdaq.com/articles/ironwood-commences-dosing-in-phase-i-study-on-iw-1973-analyst-blog-2015-03-06", "https://www.nasdaq.com/articles/ironwood-actavis-move-linzess-into-phase-ii-study-for-oic-analyst-blog-2014-10-17", "https://www.nasdaq.com/articles/sector-update-health-care-2014-10-16-0", "https://www.nasdaq.com/articles/sector-update-health-stocks-lower-pre-bell-2014-10-16", "https://www.nasdaq.com/articles/first-week-may-2015-options-trading-ironwood-pharmaceuticals-2014-09-25", "https://www.nasdaq.com/articles/irwd-makes-notable-cross-below-critical-moving-average-2014-08-21", "https://www.nasdaq.com/articles/synergy-pharma-sgyp-posts-wider-than-expected-loss-in-q2-analyst-blog-2014-08-13", "https://www.nasdaq.com/articles/5-things-actavis-plcs-management-wants-you-know-2014-11-12", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-narrows-q2-loss-revenues-down-analyst-blog-2014-08-05", "https://www.nasdaq.com/articles/questcor-qcor-misses-on-q2-earnings-beats-on-revenues-analyst-blog-2014-07-25", "https://www.nasdaq.com/articles/acelrx-pharmaceuticals-acrx-jumps%3A-stock-adds-11.7-in-session-tale-of-the-tape-2014-07-21", "https://www.nasdaq.com/articles/immunogen-imgn-soars%3A-stock-up-8.8-tale-of-the-tape-2014-07-21", "https://www.nasdaq.com/articles/synergy-pharmaceuticals-progresses-with-mid-stage-candidate-analyst-blog-2014-07-18", "https://www.nasdaq.com/articles/synergy-pharmaceuticals-plecanatide-to-move-into-phase-iii-analyst-blog-2014-07-09", "https://www.nasdaq.com/articles/synergy-pharma-posts-narrower-than-expected-q1-loss-analyst-blog-2014-05-14", "https://www.nasdaq.com/articles/earnings-up-at-jazz-pharmaceuticals-revenue-guidance-raised-analyst-blog-2014-08-06", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-narrows-q2-loss-revenues-down-analyst-blog-2014-08-05", "https://www.nasdaq.com/articles/questcor-qcor-misses-on-q2-earnings-beats-on-revenues-analyst-blog-2014-07-25", "https://www.nasdaq.com/articles/acelrx-pharmaceuticals-acrx-jumps%3A-stock-adds-11.7-in-session-tale-of-the-tape-2014-07-21", "https://www.nasdaq.com/articles/immunogen-imgn-soars%3A-stock-up-8.8-tale-of-the-tape-2014-07-21", "https://www.nasdaq.com/articles/synergy-pharmaceuticals-progresses-with-mid-stage-candidate-analyst-blog-2014-07-18", "https://www.nasdaq.com/articles/synergy-pharmaceuticals-plecanatide-to-move-into-phase-iii-analyst-blog-2014-07-09", "https://www.nasdaq.com/articles/synergy-pharma-posts-narrower-than-expected-q1-loss-analyst-blog-2014-05-14", "https://www.nasdaq.com/articles/earnings-up-at-jazz-pharmaceuticals-revenue-guidance-raised-analyst-blog-2014-08-06", "https://www.nasdaq.com/articles/healthcare-stocks-trailing-broader-markets-ironwood-pharma-climbing-late-trade-after", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-04-29", "https://www.nasdaq.com/articles/tuesdays-etf-movers-xbi-rem-2014-04-29", "https://www.nasdaq.com/articles/valeant-eyes-allergan-analyst-blog-2014-04-24", "https://www.nasdaq.com/articles/interesting-irwd-put-and-call-options-june-21st-2014-04-23", "https://www.nasdaq.com/articles/why-ironwood-pharmaceuticals-irwd-is-poised-to-beat-earnings-estimates-again-tale-of-the", "https://www.nasdaq.com/articles/irwd-makes-bullish-cross-above-critical-moving-average-2014-04-22", "https://www.nasdaq.com/articles/ironwood-up-as-loss-narrows-linzess-shines-analyst-blog-2014-04-30", "https://www.nasdaq.com/articles/first-week-april-19th-options-trading-ironwood-pharmaceuticals-irwd-2014-02-26", "https://www.nasdaq.com/articles/pre-market-most-active-feb-12-2014-nok-ato-pbra-fsl-mt-abb-optt-csiq-qqq-irwd-fb-trip-2014", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-ironwood-shares-up-analyst-blog-2014-01-22", "https://www.nasdaq.com/articles/key-pharmaceutical-stocks-ready-to-deliver-earnings-beats-earnings-esp-2014-01-16", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-inc-irwd-new-analyst-report-zacks-equity-research-zacks-equity", "https://www.nasdaq.com/articles/ironwood-up-on-job-cut-plans-analyst-blog-2014-01-10", "https://www.nasdaq.com/articles/should-you-worry-about-the-short-interest-in-ironwood-pharmaceuticals-inc.-irwd-tale-of", "https://www.nasdaq.com/articles/ironwood-initiates-gerd-study-shares-up-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/first-week-april-19th-options-trading-ironwood-pharmaceuticals-irwd-2014-02-26", "https://www.nasdaq.com/articles/pre-market-most-active-feb-12-2014-nok-ato-pbra-fsl-mt-abb-optt-csiq-qqq-irwd-fb-trip-2014", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-ironwood-shares-up-analyst-blog-2014-01-22", "https://www.nasdaq.com/articles/key-pharmaceutical-stocks-ready-to-deliver-earnings-beats-earnings-esp-2014-01-16", "https://www.nasdaq.com/articles/ironwood-pharmaceuticals-inc-irwd-new-analyst-report-zacks-equity-research-zacks-equity", "https://www.nasdaq.com/articles/ironwood-up-on-job-cut-plans-analyst-blog-2014-01-10", "https://www.nasdaq.com/articles/should-you-worry-about-the-short-interest-in-ironwood-pharmaceuticals-inc.-irwd-tale-of", "https://www.nasdaq.com/articles/ironwood-initiates-gerd-study-shares-up-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/update-on-ironwood-pharma-analyst-blog-2013-12-16", "https://www.nasdaq.com/articles/largest-option-trades-equities-2013-12-11", "https://www.nasdaq.com/articles/synergy-pharmas-q3-loss-narrower-than-expected-analyst-blog-2013-11-15", "https://www.nasdaq.com/articles/pipeline-progress-at-synergy-pharma-analyst-blog-2013-11-04", "https://www.nasdaq.com/articles/weekly-3-year-low-highlight-exc-rvbd-irwd-shos-2013-10-27", "https://www.nasdaq.com/articles/roche-and-inovio-tie-up-analyst-blog-2013-09-11", "https://www.nasdaq.com/articles/data-on-auxilium-pharmas-xiaflex-analyst-blog-2013-10-11", "https://www.nasdaq.com/articles/discovery-labs-surges-on-surfaxin-news-analyst-blog-2013-10-07", "https://www.nasdaq.com/articles/forests-patent-infringement-lawsuits-analyst-blog-2013-10-07", "https://www.nasdaq.com/articles/synergy-pharmas-pipeline-holds-promise-analyst-blog-2013-10-04", "https://www.nasdaq.com/articles/ironwood-and-astrazeneca-initiate-study-analyst-blog-2013-09-16", "https://www.nasdaq.com/articles/positive-news-on-roches-perjeta-analyst-blog-2013-09-13", "https://www.nasdaq.com/articles/data-on-novartis-ultibro-breezhaler-analyst-blog-2013-09-12", "https://www.nasdaq.com/articles/roche-and-inovio-tie-up-analyst-blog-2013-09-11", "https://www.nasdaq.com/articles/data-on-auxilium-pharmas-xiaflex-analyst-blog-2013-10-11", "https://www.nasdaq.com/articles/novartis-ilaris-approved-for-sjia-in-europe-analyst-blog-2013-09-05", "https://www.nasdaq.com/articles/setback-for-arqule-analyst-blog-2013-09-04", "https://www.nasdaq.com/articles/data-on-novartis-rlx030-analyst-blog-2013-09-03", "https://www.nasdaq.com/articles/encouraging-data-on-roches-lampalizumab-analyst-blog-2013-08-30", "https://www.nasdaq.com/articles/fda-designation-for-cprxs-firdapse-analyst-blog-2013-08-28", "https://www.nasdaq.com/articles/astellas-astagraf-xl-launched-in-u.s.-analyst-blog-2013-08-23", "https://www.nasdaq.com/articles/investors-are-betting-against-ironwood-pharmaceuticals-inc.-irwd-should-you-tale-of-the", "https://www.nasdaq.com/articles/otsuka-pharma-to-acquire-astex-pharma-shares-up-analyst-blog-2013-09-06", "https://www.nasdaq.com/articles/loss-narrows-at-synergy-pharma-in-q2-analyst-blog-2013-08-16", "https://www.nasdaq.com/articles/corcepts-q2-loss-in-line-with-expectations-analyst-blog-2013-08-12", "https://www.nasdaq.com/articles/valeant-tops-on-earnings-ups-guidance-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/valeant-acquires-bausch-lomb-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/pipeline-progress-at-synergy-pharma-analyst-blog-2013-08-06", "https://www.nasdaq.com/articles/loss-widens-at-ironwood-analyst-blog-2013-07-24", "https://www.nasdaq.com/articles/will-forest-labs-frx-beat-earnings-estimates-this-quarter-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/breakthrough-therapy-for-novartis-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/positive-data-from-synergy-pharma-analyst-blog-2013-05-24", "https://www.nasdaq.com/articles/ironwood-pharma-prices-stock-offering-analyst-blog-2013-05-23", "https://www.nasdaq.com/articles/pre-market-most-active-may-22-2013-ntap-pfe-nmr-rdsa-rdsb-nok-sne-pgti-irwd-gild-vod-znga", "https://www.nasdaq.com/articles/loss-widens-at-ironwood-analyst-blog-2013-04-24", "https://www.nasdaq.com/articles/loss-widens-at-irwd-on-higher-costs-analyst-blog-2013-01-16", "https://www.nasdaq.com/articles/alkermes-maintains-fiscal-2013-view-analyst-blog-2013-01-09", "https://www.nasdaq.com/articles/forest-settles-with-glenmark-analyst-blog-2013-01-09", "https://www.nasdaq.com/articles/irwd-launches-constella-in-europe-analyst-blog-2013-06-17", "https://www.nasdaq.com/articles/positive-data-from-synergy-pharma-analyst-blog-2013-05-24", "https://www.nasdaq.com/articles/ironwood-pharma-prices-stock-offering-analyst-blog-2013-05-23", "https://www.nasdaq.com/articles/pre-market-most-active-may-22-2013-ntap-pfe-nmr-rdsa-rdsb-nok-sne-pgti-irwd-gild-vod-znga", "https://www.nasdaq.com/articles/loss-widens-at-ironwood-analyst-blog-2013-04-24", "https://www.nasdaq.com/articles/loss-widens-at-irwd-on-higher-costs-analyst-blog-2013-01-16", "https://www.nasdaq.com/articles/alkermes-maintains-fiscal-2013-view-analyst-blog-2013-01-09", "https://www.nasdaq.com/articles/forest-settles-with-glenmark-analyst-blog-2013-01-09", "https://www.nasdaq.com/articles/irwd-launches-constella-in-europe-analyst-blog-2013-06-17", "https://www.nasdaq.com/articles/positive-results-on-sgyp-candidate-analyst-blog-2013-01-03", "https://www.nasdaq.com/articles/ironwood-pharma-upped-to-strong-buy-analyst-blog-2013-01-03", "https://www.nasdaq.com/articles/forest-labs-glenmark-tie-up-analyst-blog-2012-12-31", "https://www.nasdaq.com/articles/pipeline-progress-at-synergy-pharma-analyst-blog-2012-12-31", "https://www.nasdaq.com/articles/ironwood-anxiety-drug-in-phase-i-analyst-blog-2012-12-27", "https://www.nasdaq.com/articles/cubist-pharma-seeks-label-expansion-analyst-blog-2012-12-24", "https://www.nasdaq.com/articles/forest-launches-two-products-analyst-blog-2012-12-19", "https://www.nasdaq.com/articles/patent-challenge-for-auxilium-pharma-analyst-blog-2013-01-04", "https://www.nasdaq.com/articles/positive-results-on-sgyp-candidate-analyst-blog-2013-01-03", "https://www.nasdaq.com/articles/forest-hit-by-lexapro-generics-analyst-blog-2012-04-17", "https://www.nasdaq.com/articles/earnings-scorecard%3A-forest-labs-analyst-blog-2012-10-26", "https://www.nasdaq.com/articles/ironwood-pharma-beats-on-all-fronts-analyst-blog-2012-10-18", "https://www.nasdaq.com/articles/chmp-positive-on-ironwoods-constella-analyst-blog-2012-09-27", "https://www.nasdaq.com/articles/fda-oks-forest-ironwoods-linzess-analyst-blog-2012-08-31", "https://www.nasdaq.com/articles/hedging-ironwood-ruling-2012-08-28", "https://www.nasdaq.com/articles/forest-files-cariprazine-nda-analyst-blog-2012-12-04"], "Content": []}